Evaluation of secondary endpoints visual acuity, sphere and anatomical findings, based on intention-to-treat set (last observation carried forward, mean±SD or count (percentage); results for PP set, see online supplementary material)
| Secondary endpoint | Group† | Baseline | Week 26 | Difference week 26—baseline | Paired t-test 95% CI | ANCOVA‡, E1/2 vs C mean difference, 95% CI |
|---|---|---|---|---|---|---|
| Visual acuity, logMAR | E1 (n=98) | 1.0±0.7 | 0.3±0.4 | −0.7±0.7 | −0.8 to −0.6*** | |
| C (n=97) | 0.9±0.7 | 0.3±0.4 | −0.6±0.6 | −0.8 to −0.5*** | 0.0 (−0.1 to 0.1) | |
| E2 (n=55) | 1.0±0.6 | 0.3±0.4 | −0.8±0.6 | −0.9 to −0.6*** | ||
| C (n=60) | 1.0±0.7 | 0.3±0.3 | −0.7±0.7 | −0.9 to −0.6*** | 0.0 (−0.1 to 0.1) | |
| Sphere, dioptre | E1 (n=97) | 0.1±1.4 | −0.9±1.5 | −1.0±1.9 | −1.4 to −0.6*** | |
| C (n=96) | −0.1±1.4 | −0.2±1.9 | −0.1±1.8 | −0.5 to 0.2 | −0.8 (−1.2 to −0.3)*** | |
| E2 (n=55) | −0.1±1.2 | −0.2±1.3 | −0.1±1.5 | −0.5 to 0.3 | ||
| C (n=60) | −0.1±1.3 | −0.2±1.6 | −0.1±1.4 | −0.5 to 0.3 | −0.0 (−0.5 to 0.5), 0.878 | |
| Group† | Baseline | Week 26 | Exact Fisher test, week 26, E1/2 vs C OR, 95% CI | |||
| Retina fully attached | E1 (n=99) | 0 (0.0%) | 95 (96.0%) | |||
| C (n=98) | 0 (0.0%) | 94 (96.0%) | 1.0 (0.2 to 4.2) | |||
| E2 (n=57) | 1 (1.8%) | 54 (94.7%) | ||||
| C (n=61) | 0 (0.0%) | 57 (93.4%) | 1.3 (0.3 to 5.9) | |||
| Retina PVR grade C | E1 (n=97) | 0 (0.0%) | 4 (4.1%) | |||
| C (n=96) | 1 (1.0%) | 2 (2.1%) | 2.0 (0.4 to 11.3) | |||
| E2 (n=53) | 1 (1.9%) | 2 (3.8%) | ||||
| C (n=59) | 1 (1.7%) | 2 (3.4%) | 1.1 (0.2 to 8.2) |
*p≤0.05, **p≤0.01, ***p≤0.001.
†Patients with missing baseline value were excluded.
‡Adjusted for baseline value.ANCOVA, analysis of covariance; C, 20 gauge vitrectomy without encircling band (EB); E1, 20 gauge vitrectomy with EB; E2, 23/25 gauge vitrectomy without EB; PP, per-protocol.